RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All WHO updates
WHO
REGULATORY UPDATE
41st Invitation of Active Pharmaceutical Ingredients (APIs)
Published: 7/21/2026Detected: 5/26/2026

Summary preview

Adds three new active pharmaceutical ingredients (APIs)—buprenorphine (hydrochloride), methadone (hydrochloride), and naloxone (hydrochloride)—for products used in the treatment of substance use disorders.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
psychiatry
manufacturing
quality
clinical
safety
labeling
#WHO API invitation
#active pharmaceutical ingredient
#buprenorphine hydrochloride
#methadone hydrochloride
#naloxone hydrochloride

Official Source Document
Source Verified

Access the original document directly from WHO.

View Official Document

More from WHO

  • Invitation to a Webinar on managing reportable changes11/16/2026
  • WHO Prequalifies Two STANDARD Q Malaria Rapid Diagnostic Tests11/16/2026
  • VCP Updates - October 202611/16/2026
  • In Vitro Diagnostics Assessment Sessions for 202711/16/2026
  • New WHO Emergency Use Listing for Ebola diagnostics11/16/2026

Get WHO alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service
  • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.